Highlights

  • Lumos Diagnostics reported FY26 revenue of US$13.2 million, representing a 6% increase over the previous corresponding period.
  • FebriDx revenue rose 875% to US$3.9 million, supported mainly by sales orders from U.S. distributor PHASE Scientific.
  • More than 170 healthcare locations across 24 U.S. states were actively ordering and using FebriDx at the announcement date.
  • The company generated a Q4 operating cash inflow of US$2.7 million and ended FY26 with US$15.4 million in cash.
  • Lumos completed another BARDA pediatric study milestone and received a related payment of approximately US$0.7 million.

Lumos Diagnostics Holdings Ltd (ASX:LDX) has released its fourth-quarter FY2026 activities report, outlining higher full-year revenue, substantial growth in its FebriDx product business and continued progress in the U.S. commercial rollout of its rapid point-of-care diagnostic platform. The company also reported positive quarterly operating cash flow and a significantly increased closing cash position.

Lumos shares were trading 4.55% lower at AUD 0.10 during the morning session on 27 July 2026. Despite the decline during the session, the stock remained 50.00% higher over the past year, representing an increase of AUD 0.03. The share price performance is separate from the operational and financial developments disclosed in the quarterly update.

Lumos Diagnostics specialises in rapid point-of-care diagnostic technologies designed to help healthcare professionals diagnose and manage medical conditions. The company develops and commercialises its own diagnostic products while also providing assay development, contract manufacturing and proprietary digital reader services to external healthcare and diagnostics companies.

FY26 Revenue Increases as Product Business Expands

Lumos reported unaudited revenue of US$13.2 million for FY26, up 6% from US$12.4 million in the previous corresponding period.

The Products division generated US$4.3 million in revenue, representing growth of 135% from US$1.8 million in FY25. This improvement was primarily driven by FebriDx, which delivered revenue of US$3.9 million compared with US$0.4 million a year earlier.

The 875% increase in FebriDx revenue reflected sales orders from PHASE Scientific, Lumos’ exclusive U.S. distributor.

The company’s Services division recorded FY26 revenue of US$8.9 million, down 16% from US$10.6 million. Lumos attributed the decline mainly to a reduction in recognised Hologic intellectual property licence revenue following an extension to the Hologic fFN development timeline.

Revenue recognised from the Hologic IP licence declined from US$4.6 million in FY25 to US$1.4 million in FY26.

Excluding the reduction in licence fee revenue, project-based revenue increased by US$1.5 million to US$7.5 million, representing growth of 24%. Lumos said this reflected increased contract research and development activity and continued progress across customer projects.

Quarterly Revenue Reflects Timing and Seasonality

For the three months ended 30 June 2026, Lumos generated revenue of US$2.3 million, down 14% from US$2.6 million in the corresponding quarter.

Products revenue was US$0.2 million, representing a decline of 49%. The prior corresponding quarter included stocking orders from a former distributor that has since been replaced by PHASE.

FebriDx sales were also lower than in the third quarter of FY26 due to expected seasonal conditions and the timing of substantial PHASE orders recognised during February and March 2026.

Revenue from the third-party CorDx Flu A/B/COVID combination test did not match the prior-year contribution from Lumos’ proprietary ViraDx product. Full-year sales from the CorDx product totalled US$0.2 million, while the product line declined by US$1.1 million compared with the previous period.

Services revenue for Q4 was US$2.1 million, down 10%. Lumos continued work across 12 customer projects during the quarter, while contract research and development services revenue increased 39%.

However, services revenue was affected by lower Hologic IP licence amortisation, which fell to US$0.1 million from US$0.9 million in Q4 FY25.

FebriDx U.S. Commercialisation Continues

FebriDx is a rapid point-of-care blood test designed to help clinicians distinguish between bacterial and non-bacterial acute respiratory infections within approximately 10 minutes.

The product is registered for use in the United States, the United Kingdom, Europe, Kuwait, the United Arab Emirates and Australia.

The U.S. Food and Drug Administration granted a CLIA waiver for FebriDx on 27 March 2026. Lumos said the waiver increased the product’s addressable U.S. market by approximately 15 times, allowing it to be used across more than 300,000 healthcare locations.

These locations include urgent care centres, primary care physician offices, community health centres, retail health clinics and pharmacy-based care settings.

The company estimates that more than 80 million U.S. patients present with acute respiratory infections each year, creating a total market opportunity exceeding US$1.0 billion.

Under Lumos’ six-year exclusive U.S. distribution agreement with PHASE, which has a stated value of US$317 million, the CLIA waiver triggered a US$5.0 million payment. Lumos received the amount in April 2026.

The company also received a US$0.5 million payment from the Biomedical Advanced Research and Development Authority, or BARDA, after achieving the CLIA waiver milestone.

More Than 170 Sites Actively Using FebriDx

At the date of the quarterly announcement, more than 170 healthcare locations across 24 U.S. states were actively ordering and using FebriDx.

This total included 44 WellStreet Urgent Care sites.

WellStreet initially trialled FebriDx at one Atlanta location before agreeing to expand the program to another 43 sites across Georgia and Michigan. That rollout was completed by the middle of June 2026.

The final expansion phase is intended to extend the product across all 165 WellStreet sites over the following three to nine months, with a focus on activating as many locations as possible before the upcoming U.S. flu season.

Lumos is initially concentrating on Tier 1 and Tier 2 customers, which comprise the 100 largest urgent care operators in the United States. Together, these groups represent approximately 40% of U.S. urgent care clinics and more than 5,700 sites.

The company is supporting adoption through provider education, clinical workflow integration, marketing and reimbursement initiatives.

Lumos said more than 90% of submitted reimbursement claims had been successfully paid. The Medicare benchmark reimbursement rate is US$41.38 per test, while private insurer reimbursement has generally exceeded that amount.

Further Healthcare Networks Enter Validation

After the end of the quarter, Lumos disclosed additional commercial progress across priority U.S. accounts.

A leading regional urgent care operator owned by a major health system agreed to deploy FebriDx across more than 30 sites. These locations collectively handle an estimated 200,000 acute respiratory infection presentations annually.

Three other urgent care groups, including top-10, top-25 and top-30 operators, were progressing through clinical and economic validation across multiple locations. In total, these accounts represent more than 230 urgent care sites.

The company also secured a commitment from another top-100 urgent care organisation operated by a large not-for-profit healthcare system in the southeastern United States.

That health system includes more than 400 care locations and over 25 urgent care sites, offering a potential wider deployment opportunity if validation is successful.

Pediatric Study Reaches Another Milestone

Lumos is continuing a BARDA-funded clinical study aimed at extending FebriDx use to children aged between two and 12 years in CLIA-waived settings.

The study began in October 2025 and is being conducted across multiple U.S. clinical sites.

During Q4, Lumos completed Milestone 7 after enrolling 250 patients. This triggered a payment of US$670,000, which has since been received.

Cumulative payments under the pediatric study agreement have now reached US$2.6 million.

The broader BARDA agreement provides for milestone payments totalling US$6.2 million across 12 events, including patient recruitment, trial set-up, regulatory submission and potential FDA clearance and CLIA waiver categorisation.

Lumos expects the pediatric study to run for approximately 12 months and intends to provide another progress update closer to the end of calendar year 2026.

A successful label expansion could increase the U.S. addressable market for FebriDx by an estimated 15% to 20%.

Hologic Development Program Continues

Lumos also continued work on the next generation of Hologic’s fetal fibronectin diagnostic product, which is used in the assessment of pre-term birth risk.

The original arrangement included a US$10.0 million IP licensing agreement and a development contract initially valued at US$4.7 million.

Additional scopes of work have since increased total milestone payments under the development agreement to between US$7.0 million and US$7.7 million.

Phase 1 has been completed, while work under Phase 2 is expected to conclude by the end of August 2026.

Phase 3, which involves delivery of a working prototype, remains in progress. The addition of further assay, hardware and software work has extended the estimated completion date to approximately June 2028.

Lumos has received US$2.8 million for Phase 2 and US$1.2 million for Phase 3 to date.

Quarterly Operating Cash Flow Turns Positive

Lumos generated customer receipts of US$7.0 million in Q4 FY26, compared with US$1.8 million in the prior corresponding quarter.

The latest quarter included the US$5.0 million PHASE milestone payment.

Payments to suppliers and employees totalled US$5.8 million, up from US$3.5 million. The increase reflected business growth, inventory investment and pediatric study costs.

Government grants and tax incentives contributed US$1.7 million, comprising US$1.2 million from BARDA and US$0.5 million from the Australian research and development tax incentive.

Net operating cash inflow was US$2.7 million, compared with an outflow of US$1.7 million in Q4 FY25.

The company spent US$2.1 million on expanding manufacturing capacity at its Carlsbad facility. The work is expected to be completed in November 2026, with approximately US$0.5 million of further expenditure anticipated in the first half of FY27.

Lumos received US$13.3 million net from its institutional placement and Share Purchase Plan and another US$1.5 million from option exercises.

The company finished the quarter with US$15.4 million in cash. After the reporting period, it completed repayment of its A$5.0 million secured loan facility, leaving Lumos debt free at the announcement date.

What Could Investors Watch Next?

Lumos enters FY27 with a larger cash balance, no debt and growing commercial activity in the U.S. FebriDx business.

Key areas to monitor include expansion across WellStreet’s 165 locations, conversion of urgent care validation programs into broader network orders, reimbursement progress and utilisation rates at active sites.

Further milestones in the pediatric study, completion of the Carlsbad manufacturing expansion and delivery of Hologic development work will also remain relevant.

The company’s FY26 results show that FebriDx has become the main driver of product revenue, while the U.S. commercial opportunity has widened considerably following the CLIA waiver.